• - Serokonversionsrateb (95%-KI) 49,2% (46,4-52,0) 48,7% (44,7-52,6) - -0,5% (-5,3-4,2)
• - Seroprotektionsratec (95% KI) 96.3% (95.1-97.3) 96.7% (95.0-97.9)
• +Serokonversionsrateb (95%-KI) 49,2% (46,4-52,0) 48,7% (44,7-52,6) - -0,5% (-5,3-4,2)
• +Seroprotektionsratec (95% KI) 96.3% (95.1-97.3) 96.7% (95.0-97.9)
• - Serokonversionsrateb (95%-KI) 38,3% (35,6-41,1) 35,6% (31,9-39,5) - -2,7% (-7,2-1,9)
• - Seroprotektionsratec (95% KI) 98.4% (97.5-99.0) 98.6% (97.3-99.3)
• +Serokonversionsrateb (95%-KI) 38,3% (35,6-41,1) 35,6% (31,9-39,5) - -2,7% (-7,2-1,9)
• +Seroprotektionsratec (95% KI) 98.4% (97.5-99.0) 98.6% (97.3-99.3)
• - Serokonversionsrateb (95%-KI) 36,6% (33,9-39,3) 34,8% (31,1-38,7) - -1,8% (-6,2-2,8)
• - Seroprotektionsratec (95% KI) 93.6% (92.1-94.9) 91.8% (89.4-93.8)
• +Serokonversionsrateb (95%-KI) 36,6% (33,9-39,3) 34,8% (31,1-38,7) - -1,8% (-6,2-2,8)
• +Seroprotektionsratec (95% KI) 93.6% (92.1-94.9) 91.8% (89.4-93.8)
• - Serokonversionsrateb (95%-KI) 39,8% (37,0-42,5) 35,4% (31,7-39,2) - -4,4% (-8,9-0,2)
• - Seroprotektions-ratec (95% KI) 97.7% (96.7-98.4) 96.9% (95.2-98.1)
• +Serokonversionsrateb (95%-KI) 39,8% (37,0-42,5) 35,4% (31,7-39,2) - -4,4% (-8,9-0,2)
• +Seroprotektions-ratec (95% KI) 97.7% (96.7-98.4) 96.9% (95.2-98.1)
• - FLUCELVAX TETRA N=606 TIV1c/TIV2ca N=306/297 FLUCELVAX TETRA N=705 TIV1c/TIV2ca N=358/361
• +FLUCELVAX TETRA N=606 TIV1c/TIV2ca N=306/297 FLUCELVAX TETRA N=705 TIV1c/TIV2ca N=358/361
• - GMT (95%-KI) 1.139 (1.045-1.242) 1.138 (1.007-1.286)
• - Serokonversionsrateb (95% KI) 70% (66%-74%) 72% (67%-78%)
• - Seroprotektionsratec (95% KI) 99% (98%-100%) 99% (97%-100%)
• +GMT (95%-KI) 1.139 (1.045-1.242) 1.138 (1.007-1.286)
• +Serokonversionsrateb (95% KI) 70% (66%-74%) 72% (67%-78%)
• +Seroprotektionsratec (95% KI) 99% (98%-100%) 99% (97%-100%)
• - GMT (95%-KI) 719 (673-767) 762 (694-836)
• - Serokonversionsrateb 42% (38%-47%) 53% (46%-59%)
• - Seroprotektionsratec (95% KI) 100% (99%-100%) 100% (98%-100%)
• +GMT (95%-KI) 719 (673-767) 762 (694-836)
• +Serokonversionsrateb 42% (38%-47%) 53% (46%-59%)
• +Seroprotektionsratec (95% KI) 100% (99%-100%) 100% (98%-100%)
• - GMT (95%-KI) 200 (185-218) 200 (178-224)
• - Serokonversionsrateb 63 % (58%-67%) 63 % (57%-69%)
• - Seroprotektionsratec (95% KI) 97% (95%-98%) 97% (94%-99%)
• +GMT (95%-KI) 200 (185-218) 200 (178-224)
• +Serokonversionsrateb 63 % (58%-67%) 63 % (57%-69%)
• +Seroprotektionsratec (95% KI) 97% (95%-98%) 97% (94%-99%)
• - GMT (95%-KI) 212 (192-235) 203 (175-234)
• - Serokonversionsrateb 72% (68%-75%) 68% (62%-74%)
• - Seroprotektionsratec (95% KI) 95% (92%-96%) 91% (87%-94%)
• +GMT (95%-KI) 212 (192-235) 203 (175-234)
• +Serokonversionsrateb 72% (68%-75%) 68% (62%-74%)
• +Seroprotektionsratec (95% KI) 95% (92%-96%) 91% (87%-94%)
• - A/H1N1 0,13 5 0,22 8 1,12 43 88,2 67,4 80,3 54,7
• - B** 0 0 0 0 0,03 1 -- -- -- --
• +A/H1N1 0,13 5 0,22 8 1,12 43 88,2 67,4 80,3 54,7
• +B** 0 0 0 0 0,03 1 -- -- -- --
• - A/H1N1 0,16 6 0,27 10 1,48 57 89,3 73,0 81,5 60,9
• - B 0,79 30 0,74 27 1,59 61 49,9 18,2 53,2 22,2
• +A/H1N1 0,16 6 0,27 10 1,48 57 89,3 73,0 81,5 60,9
• +B 0,79 30 0,74 27 1,59 61 49,9 18,2 53,2 22,2
• -Medius AG, 4132 Muttenz
• +Vifor (International) Inc., St. Gallen.